158 related articles for article (PubMed ID: 25616967)
41. Radical-Mediated Thiol-Ene Strategy: Photoactivation of Thiol-Containing Drugs in Cancer Cells.
Sun S; Oliveira BL; Jiménez-Osés G; Bernardes GJL
Angew Chem Int Ed Engl; 2018 Nov; 57(48):15832-15835. PubMed ID: 30300959
[TBL] [Abstract][Full Text] [Related]
42. A concise total synthesis of largazole, solution structure, and some preliminary structure activity relationships.
Nasveschuk CG; Ungermannova D; Liu X; Phillips AJ
Org Lett; 2008 Aug; 10(16):3595-8. PubMed ID: 18616341
[TBL] [Abstract][Full Text] [Related]
43. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
44. Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases.
Al-Awadhi FH; Salvador-Reyes LA; Elsadek LA; Ratnayake R; Chen QY; Luesch H
ACS Chem Neurosci; 2020 Jul; 11(13):1937-1943. PubMed ID: 32559056
[TBL] [Abstract][Full Text] [Related]
45. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
46. Largazole and its derivatives selectively inhibit ubiquitin activating enzyme (e1).
Ungermannova D; Parker SJ; Nasveschuk CG; Wang W; Quade B; Zhang G; Kuchta RD; Phillips AJ; Liu X
PLoS One; 2012; 7(1):e29208. PubMed ID: 22279528
[TBL] [Abstract][Full Text] [Related]
47. Spiro[chromane-2,4'-piperidine]-based histone deacetylase inhibitors with improved in vivo activity.
Thaler F; Varasi M; Carenzi G; Colombo A; Abate A; Bigogno C; Boggio R; Carrara S; Cataudella T; Dal Zuffo R; Reali V; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C
ChemMedChem; 2012 Apr; 7(4):709-21. PubMed ID: 22354629
[TBL] [Abstract][Full Text] [Related]
48. T63, a new 4-arylidene curcumin analogue, induces cell cycle arrest and apoptosis through activation of the reactive oxygen species-FOXO3a pathway in lung cancer cells.
Liu H; Zhou BH; Qiu X; Wang HS; Zhang F; Fang R; Wang XF; Cai SH; Du J; Bu XZ
Free Radic Biol Med; 2012 Dec; 53(12):2204-17. PubMed ID: 23085518
[TBL] [Abstract][Full Text] [Related]
49. A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells.
Xiong F; Jiang M; Huang Z; Chen M; Chen K; Zhou J; Yin L; Tang Y; Wang M; Ye L; Zhan Z; Duan J; Fu H; Zhang X
Integr Cancer Ther; 2014 Mar; 13(2):152-60. PubMed ID: 24105357
[TBL] [Abstract][Full Text] [Related]
50. Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities.
Xi JB; Fang YF; Frett B; Zhu ML; Zhu T; Kong YN; Guan FJ; Zhao Y; Zhang XW; Li HY; Ma ML; Hu W
Eur J Med Chem; 2017 Jan; 126():1083-1106. PubMed ID: 28039836
[TBL] [Abstract][Full Text] [Related]
51. Largazole Inhibits Ocular Angiogenesis by Modulating the Expression of VEGFR2 and p21.
Qiu B; Tan A; Tan YZ; Chen QY; Luesch H; Wang X
Mar Drugs; 2021 Aug; 19(8):. PubMed ID: 34436310
[TBL] [Abstract][Full Text] [Related]
52. Largazole, an inhibitor of class I histone deacetylases, attenuates inflammatory corneal neovascularization.
Zhou H; Jiang S; Chen J; Ren X; Jin J; Su SB
Eur J Pharmacol; 2014 Oct; 740():619-26. PubMed ID: 24973692
[TBL] [Abstract][Full Text] [Related]
53. SRJ09, a promising anticancer drug lead: Elucidation of mechanisms of antiproliferative and apoptogenic effects and assessment of in vivo antitumor efficacy.
Wong CC; Lim SH; Sagineedu SR; Lajis NH; Stanslas J
Pharmacol Res; 2016 May; 107():66-78. PubMed ID: 26940565
[TBL] [Abstract][Full Text] [Related]
54. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
Li X; Hou J; Li X; Jiang Y; Liu X; Mu W; Jin Y; Zhang Y; Xu W
Eur J Med Chem; 2015 Jan; 89():628-37. PubMed ID: 25462271
[TBL] [Abstract][Full Text] [Related]
55. RL66 a second-generation curcumin analog has potent in vivo and in vitro anticancer activity in ER‑negative breast cancer models.
Yadav B; Taurin S; Larsen L; Rosengren RJ
Int J Oncol; 2012 Nov; 41(5):1723-32. PubMed ID: 22971638
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and activity of largazole analogues with linker and macrocycle modification.
Ying Y; Liu Y; Byeon SR; Kim H; Luesch H; Hong J
Org Lett; 2008 Sep; 10(18):4021-4. PubMed ID: 18707106
[TBL] [Abstract][Full Text] [Related]
57. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
Zhang Y; Feng J; Jia Y; Wang X; Zhang L; Liu C; Fang H; Xu W
J Med Chem; 2011 Apr; 54(8):2823-38. PubMed ID: 21476600
[TBL] [Abstract][Full Text] [Related]
58. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
[TBL] [Abstract][Full Text] [Related]
59. Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo.
Jiang Y; Xu J; Yue K; Huang C; Qin M; Chi D; Yu Q; Zhu Y; Hou X; Xu T; Li M; Chou CJ; Li X
J Med Chem; 2022 Jan; 65(1):285-302. PubMed ID: 34942071
[TBL] [Abstract][Full Text] [Related]
60. Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor.
Payne JE; Bonnefous C; Hassig CA; Symons KT; Guo X; Nguyen PM; Annable T; Wash PL; Hoffman TZ; Rao TS; Shiau AK; Malecha JW; Noble SA; Hager JH; Smith ND
Bioorg Med Chem Lett; 2008 Dec; 18(23):6093-6. PubMed ID: 18954983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
